KGbio is a clinical-stage biotechnology company that focuses on bringing biologics medical innovation to international markets outside the US, Canada, Western Europe, and China by in-licensing novel biologics and biosimilars in oncology and specialty therapeutic areas.

How many employees does KGbio have?

KGbio has approximately 34 employees.

What industry is KGbio in?

KGbio operates in Biotechnology.

Is KGbio still active?

Yes, KGbio was verified as an active company on February 2, 2026. Data Surfer regularly validates company information to ensure accuracy.

How do I sell to KGbio?

Research KGbio's priorities and goals, identify the right decision makers and champions, monitor for buying signals, and reach out at the right time with verified contact details.

Data Surfer

How it works Insights Pricing FAQ Contact Login

KGbio

Biotechnology

34 employees

Founded 2016

kg-biologics.com

Verified active February 2, 2026

Key Highlights

Clinical-stage biotechnology company
Focuses on markets outside US/Europe/China
In-licenses novel biologics and biosimilars
Specializes in oncology and high-specialty areas
Backed by Kalbe, Genexine, and General Atlantic

About KGbio

KGbio is a clinical-stage biotechnology company dedicated to advancing innovative biologics beyond major markets like the US, Canada, Western Europe, and China. Their core strategy involves in-licensing novel biologics and select biosimilars, typically in oncology and specialized therapeutic areas at early development stages. The company aims to develop these assets through clinical trials and regulatory approvals, subsequently out-licensing them in targeted geographies. KGbio focuses on platforms including Fc-fusion proteins, antibodies, bispecifics, ADCs, cell therapies, and therapeutic vaccines, leveraging strong financial backing from prominent Asian pharmaceutical companies and a leading US private equity firm.

Company Facts

Ownership Private Company

Funding US$55 Million

Parent Company Kalbe Genexine Biologics

Why Contact KGbio?

KGbio bridges the gap for innovative biologics by developing and out-licensing them in underserved global markets, offering significant value to both developers and patients.

Who Should Contact KGbio for Business?

Pharmaceutical companies seeking global market access for their novel biologics and biosimilars, particularly in oncology and specialty therapeutics.

More Biotechnology Companies

Worldwide Clinical Trials

3.5K employees

PLUX Biosignals

34 employees

View all Biotechnology companies

Frequently Asked Questions

What does KGbio do?: KGbio is a clinical-stage biotechnology company that focuses on bringing biologics medical innovation to international markets outside the US, Canada, Western Europe, and China by in-licensing novel biologics and biosimilars in oncology and specialty therapeutic areas.
How many employees does KGbio have?: KGbio has approximately 34 employees.
What industry is KGbio in?: KGbio operates in Biotechnology.
When was KGbio founded?: KGbio was founded in 2016.
Is KGbio still active?: Yes, KGbio was verified as an active company on February 2, 2026. Data Surfer regularly validates company information to ensure accuracy.
How do I sell to KGbio?: Research KGbio's priorities and goals, identify the right decision makers and champions, monitor for buying signals, and reach out at the right time with verified contact details. Learn how Data Surfer helps.